A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation
Authors:
Open Access
- 4 August 2016
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (11) , 1417-1425
Abstract
Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and methotrexate (n=106) with a combination of tacrolimus and sirolimus (n=103) as graft-versus host disease prophylaxis after allogeneic hematopoietic stem cell transplantation in a prospective, open, randomized trial. The hypothesis was that the tacrolimus/sirolimus regimen would lead to less acute graft-versus-host disease and reduced transplant-related mortality. There was no significant difference in the cumulative incidence of acute graft-versus-host disease of grades II‒IV (41% vs. 51%; p=0.19) or grades III-IV (13% vs. 7%; p=0.09) between the groups. Time to neutrophil engraftment (18 days vs. 17 days; p=0.24) was similar, but time to platelet engraftment was longer in cyclosporine/methotrexate patients (14 vs. 12 days; p<0.01). No significant differences in incidence of oropharyngeal mucositis, time to full donor chimerism, or number of Cytomegalovirus infections were seen between the two treatment arms, and transplant-related toxicities were equally distributed. Triglyceride (p=0.005) and cholesterol (p=0.009) levels were higher in tacrolimus/sirolimus patients. Transplant-related mortality (18% vs. 12%; p=0.40) and five-year overall survival (72% vs. 71%; p=0.71) were similar. Five-year relapse-free survival in patients with malignant diagnoses was 65% in the cyclosporine/methotrexate group and 63% in the tacrolimus/sirolimus group (p=0.73). We conclude that tacrolimus/sirolimus remains a valid and safe alternative to cyclosporine/methotrexate as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation, with comparable transplant-related outcomes. The trial was registered at ClinicalTrials.gov, identifier [NCT00993343][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00993343&atom=%2Fhaematol%2Fearly%2F2016%2F08%2F01%2Fhaematol.2016.149294.atomKeywords
This publication has 49 references indexed in Scilit:
- Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015Bone Marrow Transplantation, 2015
- Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitroJournal of General Virology, 2014
- Introduction to the Review Series on "Advances in Hematopoietic Cell Transplantation"Blood, 2014
- Prevention of graft-versus-host disease.2012
- Transplantation in adult ALLHematology-American Society Hematology Education Program, 2009
- Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell TransplantationTransplantation, 2004
- Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantationTransplantation and Cellular Therapy, 2004
- Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivoBlood, 2003
- Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reactionBlood, 2002
- LONG-TERM CYCLOSPORIN THERAPY MAY DECREASE THE RISK OF CHRONIC GRAFT-VERSUS-HOST DISEASEBritish Journal of Haematology, 1990